Immunotherapy for Non-small Cell Lung Cancer: Current Agents and Potential Molecular Targets.

Autor:	Sham NO; Department of Microbiology, Immunology & Pathology, Des Moines University, Des Moines, IA, U.S.A., Zhao L; Department of Respiratory Medicine, the 2 People's Hospital of Hefei and Hefei Hospital Affiliated to Anhui Medical University, Hefei, PR. China., Zhu Z; Department of Surgery, University of Missouri School of Medicine, Columbia, MO, U.S.A., Roy TM; Department of Surgery, University of Missouri School of Medicine, Columbia, MO, U.S.A., Xiao H; Department of Surgery, University of Missouri School of Medicine, Columbia, MO, U.S.A., Bai Q; Department of Surgery, University of Missouri School of Medicine, Columbia, MO, U.S.A., Wakefield MR; Department of Surgery, University of Missouri School of Medicine, Columbia, MO, U.S.A., Fang Y; Department of Surgery, University of Missouri School of Medicine, Columbia, MO, U.S.A. yujiang.fang@dmu.edu.; Department of Microbiology, Immunology & Pathology, Des Moines University, Des Moines, IA, U.S.A.
Jazyk:	angličtina
Zdroj:	Anticancer research [Anticancer Res] 2022 Jul; Vol. 42 (7), pp. 3275-3284.
DOI:	10.21873/anticanres.15816
Abstrakt:	From radiation therapy and surgery to chemotherapy and targeted therapy, the treatment of non-small cell lung cancer (NSCLC) has remarkably evolved over the past few decades. In recent years, immunotherapy has become an increasingly attractive area of interest in the treatment of NSCLC, especially those in advanced stages. Cytokine and immune checkpoint inhibitors are among the most studied immunotherapies for many cancer types. Herein, we provide an overview of current popular cytokine and checkpoint inhibitor treatment regimens available for patients with NSCLC. Ongoing clinic trials and novel molecular targets that are discussed here could lead to promising new treatment options for NSCLC. The evidence summarized in this review might be helpful for clinicians to better manage patients with NSCLC. (Copyright © 2022 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu